RxDoctor Payments Data

Jae Lee, MD

Clinical Cardiac Electrophysiology · Leesburg, VANPI 1083971410

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (35.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 70.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $7,385 and has fallen 94.0% since, to $446 in 2025.

$27,397in general payments, 2019–2025

Across 168 payments — averaging $163.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Abbott$4K
  • Biotronik Inc.$2K
  • Medical Device Business Services, Inc.$315
  • Boston Scientific$240
  • Biosense Webster, Inc.$235
  • plus $885 from 15 others

What the payments were for

  • Consulting fees$8,92533%
  • Speaking & faculty fees$3,18812%
  • Travel & lodging$9,76236%
  • Food & beverage$5,51020%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,397 in reported general payments places this provider in the 60th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

See all clinical cardiac electrophysiology providers in Virginia

Medicare billing

Part B allowed, 2024
$336,726
Medicare patients
1,047
Services billed
2,990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$214,750
XareltoRivaroxaban39$31,385
Dofetilide45$17,807
Flecainide Acetate119$5,641
Amiodarone Hcl89$3,659
Metoprolol Succinate97$1,416
Diltiazem 24hr Er (Cd)Diltiazem Hcl30$648
Bisoprolol Fumarate11$380
SotalolSotalol Hcl16$238
Carvedilol11$94
Metoprolol Tartrate18$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$67$214,750138 claims
Johnson & JohnsonXarelto$17$31,38539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 90 clinical cardiac electrophysiology providers in Virginia.

Other clinical cardiac electrophysiology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →